WALTHAM, Mass.--(BUSINESS WIRE)--Today, Revvity, Inc. (NYSE: RVTY) announced that its software and informatics division, Revvity Signals Software, is introducing the new Signals ChemDraw® offering, the latest advancement in the Revvity Signals Software portfolio. This innovative chemistry suite is set to transform the way researchers in the pharmaceutical and non-pharmaceutical chemical industries, as well as academia, develop and communicate complex chemical concepts and collaborate across disciplines. ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 _____________________________________ Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 940 Winter Street, Waltham, Massachusetts 02451 (Address of Principal Executive Of ices) (Zip Code) (781) 663-6900 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period ...

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today announced it will present at the following investor conferences in February and March 2024: Citi's 2024 Unplugged MedTech and Life Sciences Access Day - New York City, NY Thursday, February 29, 2024 8:00 a.m. ET - Max Krakowiak, senior vice president and chief financial officer TD Cowen 44th Annual Health Care Conference – Boston, MA Monday, March 4, 2024 9:10 a.m. ET - Prahlad Singh, president and chief executive officer Raymond James 45t ...

WALTHAM, Mass.--(BUSINESS WIRE)--Today, Revvity, Inc. (NYSE: RVTY) announced that its software and informatics division, Revvity Signals, is unveiling the Signals ClinicalTM solution, a software-as-a-service (SaaS), end-to-end clinical data science platform designed to centralize all clinical trial data, providing fast, actionable insights for quicker clinical decisions and accelerated market delivery of therapeutics. This state-of-the-art solution, when integrated with enterprise-class Spotfire visual anal ...

Revvity, Inc. (NYSE:RVTY) Q4 2023 Earnings Conference Call February 1, 2024 8:00 AM ET Company Participants Steve Willoughby - Senior Vice President, Investor Relations Prahlad Singh - Chief Executive Officer, President and Director Max Krakowiak - Senior Vice President and Chief Financial Officer Conference Call Participants Jack Meehan - Nephron Research LLC Matthew Sykes - Goldman Sachs Joshua Waldman - Cleveland Research Company LLC Patrick Donnelly - Citigroup Inc. Andrew Cooper - Raymond James Financi ...

Revvity, Inc. (RVTY) reported fourth-quarter 2023 adjusted earnings per share (EPS) of $1.25, which beat the Zacks Consensus Estimate of $1.15 by 8.7%. However, the bottom line declined 12.8% from the year-ago quarter’s level.GAAP EPS from continuing operations was 52 cents compared with 77 cents in the prior-year period. However, GAAP EPS was 64 cents, which includes earnings of 12 cents per share from discontinued operations.Price PerformanceRVTY’s shares have declined 12.6% in the past six months against ...

Revvity (RVTY) reported $695.9 million in revenue for the quarter ended December 2023, representing a year-over-year decline of 36.1%. EPS of $1.25 for the same period compares to $1.70 a year ago. ...

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter 2023 The Company reported GAAP earnings per share of $0.64, as compared to $1.01 in the same period a year ago. GAAP revenue for the quarter was $696 million, as compared to $741 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $77 million, as compared to $137 million for the s ...

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that Sophie Vandebroek and Michael Klobuchar have been elected to its board of directors, effective February 1, 2024. “I am pleased to welcome Michael Klobuchar and Sophie Vandebroek to Revvity’s board and look forward to their contributions as we execute on our strategic vision,” said Alexis Michas, non-executive chairman of the board. “Sophie brings deep acumen in AI, business processes, sustainability, and cybersecurity, alon ...

Revvity, Inc. (NYSE:RVTY) 42nd Annual J.P. Morgan Healthcare Conference Summary Company Overview - Revvity is a newly formed company, established eight months prior to the conference, resulting from the divestiture of one-third of its legacy analytical instrumentation and enterprise services business, along with the PerkinElmer brand name [3][4] - The company has an annual revenue of nearly $3 billion, focusing on high-growth markets in Life Sciences and Diagnostics, with 80% of revenue being recurring [4][5] Core Business Segments Life Sciences - Revvity's focus is on preclinical research and development, providing technology and tools to accelerate drug discovery rather than selling commodity products [4][5] - The Life Sciences segment is characterized by high-value differentiated instrumentation, which supports consumables sales [4][5] Diagnostics - The Diagnostics business generates approximately $1.4 billion in annual revenue, focusing on complex diagnostic diseases such as newborn screening and autoimmune disorders [5][6] - The company aims to bridge the gap between research and diagnostics, enhancing personalized medicine [5][6] Financial Performance and Strategy - Revvity's financial performance is driven by three pillars: customer partnerships, innovative product offerings, and strategic positioning [7][10] - The company has undergone significant portfolio transformation, acquiring over a dozen companies in the past 24 months to enhance its offerings [10][13] - The immunodiagnostic reagent and life sciences reagents segments are expected to grow double digits, providing margin expansion opportunities [11][12] Market Dynamics - The company experienced mid-single-digit growth in China despite a challenging market environment, with 17% of revenue coming from the region [12][26] - Revvity's differentiated portfolio allows it to perform better than peers in the Chinese market, even amidst pricing pressures [12][26] Future Outlook - The company anticipates a return to normal growth rates of 4% to 6% in the market, with expectations of exceeding this growth due to its differentiated portfolio [15][16] - Revvity aims for double-digit EPS growth and 75 basis points of operating margin expansion in the long term [15][23] Key Challenges and Considerations - The company noted a decline in the life sciences instrumentation segment and challenges in the software licensing business, which is expected to recover in 2024 [30][38] - The impact of budget flush dynamics in the pharma and biotech sectors has affected spending, with expectations of a gradual recovery [28][30] Capital Allocation and M&A Strategy - Revvity plans to continue pursuing acquisition opportunities that enhance its product offerings and fill gaps in its portfolio [48][49] - The integration of acquired technologies is seen as a significant opportunity for future growth [49] Conclusion - Revvity is positioned as a differentiated player in the life sciences and diagnostics markets, with a strong focus on innovation and customer partnerships, aiming for sustainable growth and improved financial performance in the coming years [16][51]